 MOUNTAIN VIEW, Calif., March 24, 2021 GLOBE NEWSWIRE -- IGM Biosciences, Inc. Nasdaq: IGMS, a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that it will report its fourth quarter and year-end 2020 financial results on Tuesday, March 30, 2021. 